<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03067441</url>
  </required_header>
  <id_info>
    <org_study_id>1002-050</org_study_id>
    <secondary_id>2016-004115-12</secondary_id>
    <nct_id>NCT03067441</nct_id>
  </id_info>
  <brief_title>Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)</brief_title>
  <official_title>A Multicenter Open-Label Extension (OLE) Study To Assess The Long-Term Safety and Efficacy of Bempedoic Acid (ETC-1002) 180 MG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Esperion Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Esperion Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if bempedoic acid (ETC-1002) is safe and well-tolerated&#xD;
      in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately&#xD;
      controlled by their current therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 3, 2017</start_date>
  <completion_date type="Actual">November 5, 2019</completion_date>
  <primary_completion_date type="Actual">November 5, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to Week 82</time_frame>
    <description>TEAEs are defined as adverse events that began or worsened in severity after the first dose of investigational medicinal product (IMP) until 30 days after the last dose in the Open-Label Extension (OLE) Study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Parent Study Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Weeks 52 and 78</measure>
    <time_frame>Baseline; Week 52 and Week 78</time_frame>
    <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: LDL-C value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Parent Study Baseline in LDL-C at Weeks 52 and 78</measure>
    <time_frame>Baseline; Week 52 and Week 78</time_frame>
    <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Mean change from Baseline was calculated as: Mean LDL-C value at Week 52/Week 78 minus Mean Parent Study Baseline value. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Parent Study Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Weeks 52 and 78</measure>
    <time_frame>Baseline; Week 52 and Week 72</time_frame>
    <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: non-HDL-C value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Parent Study Baseline in Total Cholesterol at Weeks 52 and 78</measure>
    <time_frame>Baseline; Week 52 and Week 78</time_frame>
    <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Total cholesterol value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Parent Study Baseline in Apolipoprotein B (ApoB) at Weeks 52 and 78</measure>
    <time_frame>Baseline; Week 52 and Week 78</time_frame>
    <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: ApoB value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Parent Study Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) at Weeks 52 and 78</measure>
    <time_frame>Baseline; Week 52 and Week 78</time_frame>
    <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: hs-CRP value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Parent Study Baseline in Triglycerides at Weeks 52 and 78</measure>
    <time_frame>Baseline; Week 52 and Week 78</time_frame>
    <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Triglycerides value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Parent Study Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Weeks 52 and 78</measure>
    <time_frame>Baseline; Week 52 and Week 78</time_frame>
    <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: HDL-C value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Open-Label Extension (OLE) Study Baseline in LDL-C at Weeks 52 and 78</measure>
    <time_frame>Baseline; Week 52 and Week 78</time_frame>
    <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: LDL-C value at Week 52/Week 78 minus OLE Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From OLE Baseline in LDL-C at Weeks 52 and 78</measure>
    <time_frame>Baseline; Week 52 and Week 72</time_frame>
    <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Mean change from Baseline was calculated as: Mean LDL-C value at Week 52/Week 78 minus Mean OLE Study Baseline value. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From OLE Baseline in Non-HDL-C at Weeks 52 and 78</measure>
    <time_frame>Baseline; Week 52 and Week 78</time_frame>
    <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: non-HDL-C value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From OLE Baseline in Total Cholesterol at Weeks 52 and 78</measure>
    <time_frame>Baseline; Week 52 and Week 78</time_frame>
    <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Total Cholesterol value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From OLE Baseline ApoB at Weeks 52 and 78</measure>
    <time_frame>Baseline; Week 52 and Week 78</time_frame>
    <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: ApoB value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From OLE Baseline in Hs-CRP at Weeks 52 and 78</measure>
    <time_frame>Baseline; Week 52 and Week 78</time_frame>
    <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: hs-CRP value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From OLE Baseline in Triglycerides at Weeks 52 and 78</measure>
    <time_frame>Baseline; Week 52 and Week 78</time_frame>
    <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Triglycerides value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From OLE Baseline in HDL-C at Weeks 52 and 78</measure>
    <time_frame>Baseline; Week 52 and Week 78</time_frame>
    <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: HDL-C value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1462</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Atherosclerotic Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Open-Label bempedoic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bempedoic acid 180 mg tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bempedoic acid</intervention_name>
    <description>bempedoic acid 180 mg tablets taken orally, once per day.</description>
    <arm_group_label>Open-Label bempedoic acid</arm_group_label>
    <other_name>ETC-1002</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Successfully completed CLEAR Harmony (1002-040) parent study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Experienced a treatment-related SAE that led to study drug discontinuation in the&#xD;
             CLEAR Harmony (1002-040) parent study.&#xD;
&#xD;
          -  Medical condition requires lipid measurement and/or adjustment of background&#xD;
             lipid-regulating therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Esperion Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jedidiah Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L-MARC Research Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentral Clinical Research Services</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.who.int/mediacentre/factsheets/fs317/en/</url>
    <description>World Health Organization Fact Sheet No. 317</description>
  </link>
  <link>
    <url>https://thefhfoundation.org/about-fh/what-is-familial-hypercholesterolemia</url>
    <description>Familial Hypercholesterolemia Foundation</description>
  </link>
  <link>
    <url>https://rarediseases.org/rare-diseases/familial-hypercholesterolemia/</url>
    <description>National Organization for Rare Disorders - Familial Hypercholesterolemia</description>
  </link>
  <link>
    <url>https://www.nejm.org/doi/full/10.1056/NEJMoa1803917</url>
    <description>CLEAR Harmony - Reference to the Parent Study (NCT02666664)</description>
  </link>
  <reference>
    <citation>Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, Birch CM, Smith BK, Filippov S, Groot PHE, Steinberg GR, Lalwani ND. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016 Nov 28;7:13457. doi: 10.1038/ncomms13457.</citation>
    <PMID>27892461</PMID>
  </reference>
  <reference>
    <citation>Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45. doi: 10.1161/01.cir.0000437738.63853.7a. Epub 2013 Nov 12. Erratum in: Circulation. 2014 Jun 24;129(25 Suppl 2):S46-8. Erratum in: Circulation. 2015 Dec 22;132(25):e396.</citation>
    <PMID>24222016</PMID>
  </reference>
  <reference>
    <citation>Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, Daniels SR, Gidding SS, de Ferranti SD, Ito MK, McGowan MP, Moriarty PM, Cromwell WC, Ross JL, Ziajka PE; National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun;5(3 Suppl):S1-8. doi: 10.1016/j.jacl.2011.04.003. Epub 2011 Apr 12.</citation>
    <PMID>21600525</PMID>
  </reference>
  <reference>
    <citation>Pollex RL, Joy TR, Hegele RA. Emerging antidyslipidemic drugs. Expert Opin Emerg Drugs. 2008 Jun;13(2):363-81. doi: 10.1517/14728214.13.2.363 . Review.</citation>
    <PMID>18537526</PMID>
  </reference>
  <reference>
    <citation>Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W; Atherosclerosis Risk in Communities Study Group. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001 Sep 4;104(10):1108-13.</citation>
    <PMID>11535564</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 24, 2017</study_first_submitted>
  <study_first_submitted_qc>February 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <results_first_submitted>November 4, 2020</results_first_submitted>
  <results_first_submitted_qc>November 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 22, 2020</results_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hyperlipidemia</keyword>
  <keyword>cholesterol</keyword>
  <keyword>heterozygous familial hypercholesterolemia</keyword>
  <keyword>atherosclerotic cardiovascular disease</keyword>
  <keyword>ASCVD</keyword>
  <keyword>HeFH</keyword>
  <keyword>LDL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT03067441/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT03067441/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>After successfully completing 52 weeks of treatment in the parent study, Study 1002-040 (NCT02666664), and meeting entry criteria, participants could enrol into this Open-label Extension (OLE) study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo; Bempedoic Acid</title>
          <description>In the parent study (Study 1002-040), participants received placebo tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 milligrams (mg) once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of investigational medicinal product (IMP).</description>
        </group>
        <group group_id="P2">
          <title>Bempedoic Acid; Bempedoic Acid</title>
          <description>In the parent study, participants received bempedoic acid 180 mg tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="492"/>
                <participants group_id="P2" count="970"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="459"/>
                <participants group_id="P2" count="913"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated by Sponsor or Investigator</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline data are reported for members of the Safety Population, comprised of all enrolled participants who received at least 1 dose of bempedoic acid in the Open-Label Extension (OLE) Study.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo; Bempedoic Acid</title>
          <description>In the parent study (Study 1002-040), participants received placebo tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 milligrams (mg) once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of investigational medicinal product (IMP).</description>
        </group>
        <group group_id="B2">
          <title>Bempedoic Acid; Bempedoic Acid</title>
          <description>In the parent study, participants received bempedoic acid 180 mg tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="492"/>
            <count group_id="B2" value="970"/>
            <count group_id="B3" value="1462"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="492"/>
                    <count group_id="B2" value="970"/>
                    <count group_id="B3" value="1462"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.5" spread="8.54"/>
                    <measurement group_id="B2" value="66.5" spread="8.81"/>
                    <measurement group_id="B3" value="66.9" spread="8.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="492"/>
                    <count group_id="B2" value="970"/>
                    <count group_id="B3" value="1462"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="239"/>
                    <measurement group_id="B3" value="381"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="350"/>
                    <measurement group_id="B2" value="731"/>
                    <measurement group_id="B3" value="1081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="492"/>
                    <count group_id="B2" value="970"/>
                    <count group_id="B3" value="1462"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="480"/>
                    <measurement group_id="B2" value="931"/>
                    <measurement group_id="B3" value="1411"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low-density lipoprotein cholesterol (LDL-C): Parent Study</title>
          <description>Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1)</description>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="492"/>
                    <count group_id="B2" value="970"/>
                    <count group_id="B3" value="1462"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98.96" spread="24.171"/>
                    <measurement group_id="B2" value="102.94" spread="29.899"/>
                    <measurement group_id="B3" value="101.60" spread="28.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-high-density lipoprotein cholesterol (N-HDL-C): Parent Study</title>
          <description>Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1).</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="492"/>
                    <count group_id="B2" value="970"/>
                    <count group_id="B3" value="1462"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126.41" spread="28.531"/>
                    <measurement group_id="B2" value="130.09" spread="34.727"/>
                    <measurement group_id="B3" value="128.85" spread="32.809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total cholesterol: Parent Study</title>
          <description>Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1).</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="492"/>
                    <count group_id="B2" value="970"/>
                    <count group_id="B3" value="1462"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="175.33" spread="30.026"/>
                    <measurement group_id="B2" value="178.94" spread="36.057"/>
                    <measurement group_id="B3" value="177.73" spread="34.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein B: Parent Study</title>
          <description>Baseline was defined as the last value prior to first dose of study drug.</description>
          <population>Only participants with non-missing data were analysed.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="487"/>
                    <count group_id="B2" value="969"/>
                    <count group_id="B3" value="1456"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85.1" spread="19.25"/>
                    <measurement group_id="B2" value="88.2" spread="21.71"/>
                    <measurement group_id="B3" value="87.2" spread="20.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High-sensitivity C-reactive protein (hs-CRP): Parent Study</title>
          <description>Baseline was defined as the last value prior to the first dose of study drug.</description>
          <population>Only participants with non-missing data were analysed.</population>
          <units>milligrams per Liter (mg/L)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="490"/>
                    <count group_id="B2" value="969"/>
                    <count group_id="B3" value="1459"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.515" lower_limit="0.810" upper_limit="3.490"/>
                    <measurement group_id="B2" value="1.500" lower_limit="0.700" upper_limit="3.220"/>
                    <measurement group_id="B3" value="1.510" lower_limit="0.750" upper_limit="3.320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides: Parent Study</title>
          <description>Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1).</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="492"/>
                    <count group_id="B2" value="970"/>
                    <count group_id="B3" value="1462"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122.00" lower_limit="97.50" upper_limit="169.25"/>
                    <measurement group_id="B2" value="125.00" lower_limit="97.00" upper_limit="164.50"/>
                    <measurement group_id="B3" value="124.00" lower_limit="97.50" upper_limit="166.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High-density lipoprotein cholesterol (HDL-C): Parent Study</title>
          <description>Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1).</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="492"/>
                    <count group_id="B2" value="970"/>
                    <count group_id="B3" value="1462"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.93" spread="11.206"/>
                    <measurement group_id="B2" value="48.82" spread="11.790"/>
                    <measurement group_id="B3" value="48.86" spread="11.593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL-C: OLE Study</title>
          <description>Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="492"/>
                    <count group_id="B2" value="970"/>
                    <count group_id="B3" value="1462"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99.5" spread="28.59"/>
                    <measurement group_id="B2" value="86.6" spread="30.18"/>
                    <measurement group_id="B3" value="91.0" spread="30.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>N-HDL-C: OLE Study</title>
          <description>Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="492"/>
                    <count group_id="B2" value="970"/>
                    <count group_id="B3" value="1462"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126.1" spread="32.61"/>
                    <measurement group_id="B2" value="113.7" spread="34.57"/>
                    <measurement group_id="B3" value="117.9" spread="34.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total cholesterol: OLE Study</title>
          <description>Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="492"/>
                    <count group_id="B2" value="970"/>
                    <count group_id="B3" value="1462"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="175.2" spread="34.23"/>
                    <measurement group_id="B2" value="159.8" spread="36.41"/>
                    <measurement group_id="B3" value="165.0" spread="36.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein B: OLE Study</title>
          <description>Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="492"/>
                    <count group_id="B2" value="970"/>
                    <count group_id="B3" value="1462"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87.6" spread="22.74"/>
                    <measurement group_id="B2" value="80.4" spread="21.31"/>
                    <measurement group_id="B3" value="82.8" spread="22.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>hs-CRP: OLE Study</title>
          <description>Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="492"/>
                    <count group_id="B2" value="970"/>
                    <count group_id="B3" value="1462"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.560" lower_limit="0.745" upper_limit="3.015"/>
                    <measurement group_id="B2" value="1.250" lower_limit="0.620" upper_limit="2.480"/>
                    <measurement group_id="B3" value="1.325" lower_limit="0.650" upper_limit="2.650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides: OLE Study</title>
          <description>Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="492"/>
                    <count group_id="B2" value="970"/>
                    <count group_id="B3" value="1462"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120.0" lower_limit="91.5" upper_limit="165.0"/>
                    <measurement group_id="B2" value="121.0" lower_limit="88.0" upper_limit="172.0"/>
                    <measurement group_id="B3" value="120.0" lower_limit="88.0" upper_limit="169.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HDL-C: OLE Study</title>
          <description>Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="492"/>
                    <count group_id="B2" value="970"/>
                    <count group_id="B3" value="1462"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.0" spread="11.72"/>
                    <measurement group_id="B2" value="46.1" spread="13.00"/>
                    <measurement group_id="B3" value="47.1" spread="12.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
        <description>TEAEs are defined as adverse events that began or worsened in severity after the first dose of investigational medicinal product (IMP) until 30 days after the last dose in the Open-Label Extension (OLE) Study.</description>
        <time_frame>Up to Week 82</time_frame>
        <population>Safety Population: all enrolled participants who received at least 1 dose of bempedoic acid in the OLE Study</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo; Bempedoic Acid</title>
            <description>In the parent study (Study 1002-040), participants received placebo tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 milligrams (mg) once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of investigational medicinal product (IMP).</description>
          </group>
          <group group_id="O2">
            <title>Bempedoic Acid; Bempedoic Acid</title>
            <description>In the parent study, participants received bempedoic acid 180 mg tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O3">
            <title>OLE Bempedoic Acid</title>
            <description>In the parent study, participants received either bempedoic acid 180 mg tablet or matching placebo, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
          <description>TEAEs are defined as adverse events that began or worsened in severity after the first dose of investigational medicinal product (IMP) until 30 days after the last dose in the Open-Label Extension (OLE) Study.</description>
          <population>Safety Population: all enrolled participants who received at least 1 dose of bempedoic acid in the OLE Study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="970"/>
                <count group_id="O3" value="1462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="385"/>
                    <measurement group_id="O2" value="758"/>
                    <measurement group_id="O3" value="1143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="202"/>
                    <measurement group_id="O3" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with TEAEs of mild severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="195"/>
                    <measurement group_id="O3" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with TEAEs of moderate severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211"/>
                    <measurement group_id="O2" value="403"/>
                    <measurement group_id="O3" value="614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with TEAEs of severe severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="160"/>
                    <measurement group_id="O3" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Parent Study Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Weeks 52 and 78</title>
        <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: LDL-C value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.</description>
        <time_frame>Baseline; Week 52 and Week 78</time_frame>
        <population>Safety Population. Only participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo; Bempedoic Acid</title>
            <description>In the parent study (Study 1002-040), participants received placebo tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 milligrams (mg) once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O2">
            <title>Bempedoic Acid; Bempedoic Acid</title>
            <description>In the parent study, participants received bempedoic acid 180 mg tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O3">
            <title>OLE Bempedoic Acid</title>
            <description>In the parent study, participants received either bempedoic acid 180 mg tablet or matching placebo, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Parent Study Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Weeks 52 and 78</title>
          <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: LDL-C value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.</description>
          <population>Safety Population. Only participants with available data were analyzed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="970"/>
                <count group_id="O3" value="1462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="464"/>
                    <count group_id="O2" value="909"/>
                    <count group_id="O3" value="1373"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.82" spread="23.419"/>
                    <measurement group_id="O2" value="-13.80" spread="25.018"/>
                    <measurement group_id="O3" value="-13.47" spread="24.485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="433"/>
                    <count group_id="O2" value="865"/>
                    <count group_id="O3" value="1298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.99" spread="23.660"/>
                    <measurement group_id="O2" value="-14.15" spread="25.113"/>
                    <measurement group_id="O3" value="-14.43" spread="24.632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Parent Study Baseline in LDL-C at Weeks 52 and 78</title>
        <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Mean change from Baseline was calculated as: Mean LDL-C value at Week 52/Week 78 minus Mean Parent Study Baseline value. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.</description>
        <time_frame>Baseline; Week 52 and Week 78</time_frame>
        <population>Safety Population. Only participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo; Bempedoic Acid</title>
            <description>In the parent study (Study 1002-040), participants received placebo tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 milligrams (mg) once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O2">
            <title>Bempedoic Acid; Bempedoic Acid</title>
            <description>In the parent study, participants received bempedoic acid 180 mg tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O3">
            <title>OLE Bempedoic Acid</title>
            <description>In the parent study, participants received either bempedoic acid 180 mg tablet or matching placebo, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Parent Study Baseline in LDL-C at Weeks 52 and 78</title>
          <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Mean change from Baseline was calculated as: Mean LDL-C value at Week 52/Week 78 minus Mean Parent Study Baseline value. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.</description>
          <population>Safety Population. Only participants with available data were analyzed.</population>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="970"/>
                <count group_id="O3" value="1462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="464"/>
                    <count group_id="O2" value="909"/>
                    <count group_id="O3" value="1373"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.08" spread="24.995"/>
                    <measurement group_id="O2" value="-15.77" spread="28.123"/>
                    <measurement group_id="O3" value="-15.19" spread="27.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="433"/>
                    <count group_id="O2" value="865"/>
                    <count group_id="O3" value="1298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.11" spread="25.628"/>
                    <measurement group_id="O2" value="-16.04" spread="28.929"/>
                    <measurement group_id="O3" value="-16.06" spread="27.862"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Parent Study Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Weeks 52 and 78</title>
        <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: non-HDL-C value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.</description>
        <time_frame>Baseline; Week 52 and Week 72</time_frame>
        <population>Safety Population. Only participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo; Bempedoic Acid</title>
            <description>In the parent study (Study 1002-040), participants received placebo tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 milligrams (mg) once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O2">
            <title>Bempedoic Acid; Bempedoic Acid</title>
            <description>In the parent study, participants received bempedoic acid 180 mg tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O3">
            <title>OLE Bempedoic Acid</title>
            <description>In the parent study, participants received either bempedoic acid 180 mg tablet or matching placebo, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Parent Study Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Weeks 52 and 78</title>
          <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: non-HDL-C value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.</description>
          <population>Safety Population. Only participants with available data were analyzed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="970"/>
                <count group_id="O3" value="1462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="463"/>
                    <count group_id="O2" value="909"/>
                    <count group_id="O3" value="1372"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.60" spread="20.722"/>
                    <measurement group_id="O2" value="-10.55" spread="22.682"/>
                    <measurement group_id="O3" value="-10.57" spread="22.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="433"/>
                    <count group_id="O2" value="865"/>
                    <count group_id="O3" value="1298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.50" spread="22.081"/>
                    <measurement group_id="O2" value="-10.82" spread="23.910"/>
                    <measurement group_id="O3" value="-11.38" spread="23.321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Parent Study Baseline in Total Cholesterol at Weeks 52 and 78</title>
        <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Total cholesterol value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.</description>
        <time_frame>Baseline; Week 52 and Week 78</time_frame>
        <population>Safety Population. Only participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo; Bempedoic Acid</title>
            <description>In the parent study (Study 1002-040), participants received placebo tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 milligrams (mg) once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O2">
            <title>Bempedoic Acid; Bempedoic Acid</title>
            <description>In the parent study, participants received bempedoic acid 180 mg tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O3">
            <title>OLE Bempedoic Acid</title>
            <description>In the parent study, participants received either bempedoic acid 180 mg tablet or matching placebo, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Parent Study Baseline in Total Cholesterol at Weeks 52 and 78</title>
          <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Total cholesterol value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.</description>
          <population>Safety Population. Only participants with available data were analyzed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="970"/>
                <count group_id="O3" value="1462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="464"/>
                    <count group_id="O2" value="910"/>
                    <count group_id="O3" value="1374"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.01" spread="15.961"/>
                    <measurement group_id="O2" value="-9.79" spread="16.893"/>
                    <measurement group_id="O3" value="-9.53" spread="16.582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="433"/>
                    <count group_id="O2" value="865"/>
                    <count group_id="O3" value="1298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.15" spread="16.541"/>
                    <measurement group_id="O2" value="-9.34" spread="18.030"/>
                    <measurement group_id="O3" value="-9.61" spread="17.545"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Parent Study Baseline in Apolipoprotein B (ApoB) at Weeks 52 and 78</title>
        <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: ApoB value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.</description>
        <time_frame>Baseline; Week 52 and Week 78</time_frame>
        <population>Safety Population. Only participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo; Bempedoic Acid</title>
            <description>In the parent study (Study 1002-040), participants received placebo tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 milligrams (mg) once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O2">
            <title>Bempedoic Acid; Bempedoic Acid</title>
            <description>In the parent study, participants received bempedoic acid 180 mg tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O3">
            <title>OLE Bempedoic Acid</title>
            <description>In the parent study, participants received either bempedoic acid 180 mg tablet or matching placebo, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Parent Study Baseline in Apolipoprotein B (ApoB) at Weeks 52 and 78</title>
          <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: ApoB value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.</description>
          <population>Safety Population. Only participants with available data were analyzed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="970"/>
                <count group_id="O3" value="1462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="458"/>
                    <count group_id="O2" value="905"/>
                    <count group_id="O3" value="1363"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.5" spread="20.52"/>
                    <measurement group_id="O2" value="-8.8" spread="21.89"/>
                    <measurement group_id="O3" value="-8.4" spread="21.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="424"/>
                    <count group_id="O2" value="858"/>
                    <count group_id="O3" value="1282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6" spread="22.15"/>
                    <measurement group_id="O2" value="-7.0" spread="22.33"/>
                    <measurement group_id="O3" value="-7.2" spread="22.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Parent Study Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) at Weeks 52 and 78</title>
        <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: hs-CRP value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.</description>
        <time_frame>Baseline; Week 52 and Week 78</time_frame>
        <population>Safety Population. Only participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo; Bempedoic Acid</title>
            <description>In the parent study (Study 1002-040), participants received placebo tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 milligrams (mg) once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O2">
            <title>Bempedoic Acid; Bempedoic Acid</title>
            <description>In the parent study, participants received bempedoic acid 180 mg tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O3">
            <title>OLE Bempedoic Acid</title>
            <description>In the parent study, participants received either bempedoic acid 180 mg tablet or matching placebo, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Parent Study Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) at Weeks 52 and 78</title>
          <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: hs-CRP value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.</description>
          <population>Safety Population. Only participants with available data were analyzed.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="970"/>
                <count group_id="O3" value="1462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="462"/>
                    <count group_id="O2" value="908"/>
                    <count group_id="O3" value="1370"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.553" lower_limit="-53.120" upper_limit="44.167"/>
                    <measurement group_id="O2" value="-19.709" lower_limit="-52.617" upper_limit="34.151"/>
                    <measurement group_id="O3" value="-16.476" lower_limit="-52.874" upper_limit="41.667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="431"/>
                    <count group_id="O2" value="865"/>
                    <count group_id="O3" value="1296"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.005" lower_limit="-50.510" upper_limit="44.000"/>
                    <measurement group_id="O2" value="-18.065" lower_limit="-51.701" upper_limit="50.505"/>
                    <measurement group_id="O3" value="-16.740" lower_limit="-51.577" upper_limit="48.279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Parent Study Baseline in Triglycerides at Weeks 52 and 78</title>
        <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Triglycerides value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.</description>
        <time_frame>Baseline; Week 52 and Week 78</time_frame>
        <population>Safety Population. Only participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo; Bempedoic Acid</title>
            <description>In the parent study (Study 1002-040), participants received placebo tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 milligrams (mg) once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O2">
            <title>Bempedoic Acid; Bempedoic Acid</title>
            <description>In the parent study, participants received bempedoic acid 180 mg tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O3">
            <title>OLE Bempedoic Acid</title>
            <description>In the parent study, participants received either bempedoic acid 180 mg tablet or matching placebo, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Parent Study Baseline in Triglycerides at Weeks 52 and 78</title>
          <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Triglycerides value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.</description>
          <population>Safety Population. Only participants with available data were analyzed.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="970"/>
                <count group_id="O3" value="1462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="464"/>
                    <count group_id="O2" value="909"/>
                    <count group_id="O3" value="1373"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.31" lower_limit="-24.08" upper_limit="21.75"/>
                    <measurement group_id="O2" value="-3.21" lower_limit="-22.76" upper_limit="23.50"/>
                    <measurement group_id="O3" value="-3.49" lower_limit="-23.02" upper_limit="22.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="433"/>
                    <count group_id="O2" value="865"/>
                    <count group_id="O3" value="1298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.00" lower_limit="-25.54" upper_limit="24.26"/>
                    <measurement group_id="O2" value="-2.60" lower_limit="-21.41" upper_limit="27.47"/>
                    <measurement group_id="O3" value="-3.08" lower_limit="-22.78" upper_limit="26.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Parent Study Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Weeks 52 and 78</title>
        <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: HDL-C value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.</description>
        <time_frame>Baseline; Week 52 and Week 78</time_frame>
        <population>Safety Population. Only participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo; Bempedoic Acid</title>
            <description>In the parent study (Study 1002-040), participants received placebo tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 milligrams (mg) once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O2">
            <title>Bempedoic Acid; Bempedoic Acid</title>
            <description>In the parent study, participants received bempedoic acid 180 mg tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O3">
            <title>OLE Bempedoic Acid</title>
            <description>In the parent study, participants received either bempedoic acid 180 mg tablet or matching placebo, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Parent Study Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Weeks 52 and 78</title>
          <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: HDL-C value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.</description>
          <population>Safety Population. Only participants with available data were analyzed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="970"/>
                <count group_id="O3" value="1462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="464"/>
                    <count group_id="O2" value="907"/>
                    <count group_id="O3" value="1371"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.54" spread="16.747"/>
                    <measurement group_id="O2" value="-7.06" spread="15.638"/>
                    <measurement group_id="O3" value="-6.20" spread="16.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="433"/>
                    <count group_id="O2" value="863"/>
                    <count group_id="O3" value="1296"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.42" spread="17.555"/>
                    <measurement group_id="O2" value="-4.91" spread="16.731"/>
                    <measurement group_id="O3" value="-4.41" spread="17.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Open-Label Extension (OLE) Study Baseline in LDL-C at Weeks 52 and 78</title>
        <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: LDL-C value at Week 52/Week 78 minus OLE Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
        <time_frame>Baseline; Week 52 and Week 78</time_frame>
        <population>Safety Population. Only participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo; Bempedoic Acid</title>
            <description>In the parent study (Study 1002-040), participants received placebo tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 milligrams (mg) once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O2">
            <title>Bempedoic Acid; Bempedoic Acid</title>
            <description>In the parent study, participants received bempedoic acid 180 mg tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O3">
            <title>OLE Bempedoic Acid</title>
            <description>In the parent study, participants received either bempedoic acid 180 mg tablet or matching placebo, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Open-Label Extension (OLE) Study Baseline in LDL-C at Weeks 52 and 78</title>
          <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: LDL-C value at Week 52/Week 78 minus OLE Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
          <population>Safety Population. Only participants with available data were analyzed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="970"/>
                <count group_id="O3" value="1462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="464"/>
                    <count group_id="O2" value="909"/>
                    <count group_id="O3" value="1373"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.4" spread="23.79"/>
                    <measurement group_id="O2" value="3.6" spread="27.49"/>
                    <measurement group_id="O3" value="-1.8" spread="27.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="433"/>
                    <count group_id="O2" value="865"/>
                    <count group_id="O3" value="1298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.3" spread="25.79"/>
                    <measurement group_id="O2" value="3.7" spread="30.63"/>
                    <measurement group_id="O3" value="-2.3" spread="30.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From OLE Baseline in LDL-C at Weeks 52 and 78</title>
        <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Mean change from Baseline was calculated as: Mean LDL-C value at Week 52/Week 78 minus Mean OLE Study Baseline value. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
        <time_frame>Baseline; Week 52 and Week 72</time_frame>
        <population>Safety Population. Only participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo; Bempedoic Acid</title>
            <description>In the parent study (Study 1002-040), participants received placebo tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 milligrams (mg) once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O2">
            <title>Bempedoic Acid; Bempedoic Acid</title>
            <description>In the parent study, participants received bempedoic acid 180 mg tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O3">
            <title>OLE Bempedoic Acid</title>
            <description>In the parent study, participants received either bempedoic acid 180 mg tablet or matching placebo, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From OLE Baseline in LDL-C at Weeks 52 and 78</title>
          <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Mean change from Baseline was calculated as: Mean LDL-C value at Week 52/Week 78 minus Mean OLE Study Baseline value. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
          <population>Safety Population. Only participants with available data were analyzed.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="970"/>
                <count group_id="O3" value="1462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="464"/>
                    <count group_id="O2" value="909"/>
                    <count group_id="O3" value="1373"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.7" spread="25.63"/>
                    <measurement group_id="O2" value="0.6" spread="24.92"/>
                    <measurement group_id="O3" value="-4.6" spread="26.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="433"/>
                    <count group_id="O2" value="865"/>
                    <count group_id="O3" value="1298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.0" spread="28.56"/>
                    <measurement group_id="O2" value="0.2" spread="26.04"/>
                    <measurement group_id="O3" value="-5.5" spread="28.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From OLE Baseline in Non-HDL-C at Weeks 52 and 78</title>
        <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: non-HDL-C value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
        <time_frame>Baseline; Week 52 and Week 78</time_frame>
        <population>Safety Population. Only participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo; Bempedoic Acid</title>
            <description>In the parent study (Study 1002-040), participants received placebo tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 milligrams (mg) once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O2">
            <title>Bempedoic Acid; Bempedoic Acid</title>
            <description>In the parent study, participants received bempedoic acid 180 mg tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O3">
            <title>OLE Bempedoic Acid</title>
            <description>In the parent study, participants received either bempedoic acid 180 mg tablet or matching placebo, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From OLE Baseline in Non-HDL-C at Weeks 52 and 78</title>
          <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: non-HDL-C value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
          <population>Safety Population. Only participants with available data were analyzed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="970"/>
                <count group_id="O3" value="1462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="463"/>
                    <count group_id="O2" value="909"/>
                    <count group_id="O3" value="1372"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="20.81"/>
                    <measurement group_id="O2" value="2.9" spread="23.98"/>
                    <measurement group_id="O3" value="-1.4" spread="23.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="433"/>
                    <count group_id="O2" value="865"/>
                    <count group_id="O3" value="1298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.8" spread="23.08"/>
                    <measurement group_id="O2" value="3.1" spread="28.02"/>
                    <measurement group_id="O3" value="-1.9" spread="27.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From OLE Baseline in Total Cholesterol at Weeks 52 and 78</title>
        <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Total Cholesterol value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
        <time_frame>Baseline; Week 52 and Week 78</time_frame>
        <population>Safety Population. Only participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo; Bempedoic Acid</title>
            <description>In the parent study (Study 1002-040), participants received placebo tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 milligrams (mg) once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O2">
            <title>Bempedoic Acid; Bempedoic Acid</title>
            <description>In the parent study, participants received bempedoic acid 180 mg tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O3">
            <title>OLE Bempedoic Acid</title>
            <description>In the parent study, participants received either bempedoic acid 180 mg tablet or matching placebo, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From OLE Baseline in Total Cholesterol at Weeks 52 and 78</title>
          <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Total Cholesterol value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
          <population>Safety Population. Only participants with available data were analyzed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="970"/>
                <count group_id="O3" value="1462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="464"/>
                    <count group_id="O2" value="910"/>
                    <count group_id="O3" value="1374"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="15.78"/>
                    <measurement group_id="O2" value="1.3" spread="17.23"/>
                    <measurement group_id="O3" value="-2.1" spread="17.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="433"/>
                    <count group_id="O2" value="865"/>
                    <count group_id="O3" value="1298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.7" spread="17.39"/>
                    <measurement group_id="O2" value="2.1" spread="19.88"/>
                    <measurement group_id="O3" value="-1.8" spread="19.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From OLE Baseline ApoB at Weeks 52 and 78</title>
        <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: ApoB value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
        <time_frame>Baseline; Week 52 and Week 78</time_frame>
        <population>Safety Population. Only participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo; Bempedoic Acid</title>
            <description>In the parent study (Study 1002-040), participants received placebo tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 milligrams (mg) once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O2">
            <title>Bempedoic Acid; Bempedoic Acid</title>
            <description>In the parent study, participants received bempedoic acid 180 mg tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O3">
            <title>OLE Bempedoic Acid</title>
            <description>In the parent study, participants received either bempedoic acid 180 mg tablet or matching placebo, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From OLE Baseline ApoB at Weeks 52 and 78</title>
          <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: ApoB value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
          <population>Safety Population. Only participants with available data were analyzed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="970"/>
                <count group_id="O3" value="1462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="463"/>
                    <count group_id="O2" value="906"/>
                    <count group_id="O3" value="1369"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="19.94"/>
                    <measurement group_id="O2" value="0.2" spread="21.48"/>
                    <measurement group_id="O3" value="-3.2" spread="21.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="858"/>
                    <count group_id="O3" value="1286"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.2" spread="21.84"/>
                    <measurement group_id="O2" value="2.4" spread="23.16"/>
                    <measurement group_id="O3" value="-1.8" spread="23.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From OLE Baseline in Hs-CRP at Weeks 52 and 78</title>
        <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: hs-CRP value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
        <time_frame>Baseline; Week 52 and Week 78</time_frame>
        <population>Safety Population. Only participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo; Bempedoic Acid</title>
            <description>In the parent study (Study 1002-040), participants received placebo tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 milligrams (mg) once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O2">
            <title>Bempedoic Acid; Bempedoic Acid</title>
            <description>In the parent study, participants received bempedoic acid 180 mg tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O3">
            <title>OLE Bempedoic Acid</title>
            <description>In the parent study, participants received either bempedoic acid 180 mg tablet or matching placebo, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From OLE Baseline in Hs-CRP at Weeks 52 and 78</title>
          <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: hs-CRP value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
          <population>Safety Population. Only participants with available data were analyzed.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="970"/>
                <count group_id="O3" value="1462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="464"/>
                    <count group_id="O2" value="909"/>
                    <count group_id="O3" value="1373"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.720" lower_limit="-50.315" upper_limit="38.433"/>
                    <measurement group_id="O2" value="-2.174" lower_limit="-39.583" upper_limit="61.765"/>
                    <measurement group_id="O3" value="-4.856" lower_limit="-43.750" upper_limit="52.800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="433"/>
                    <count group_id="O2" value="865"/>
                    <count group_id="O3" value="1298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.953" lower_limit="-50.549" upper_limit="43.333"/>
                    <measurement group_id="O2" value="3.774" lower_limit="-36.842" upper_limit="69.136"/>
                    <measurement group_id="O3" value="-2.538" lower_limit="-41.509" upper_limit="60.268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From OLE Baseline in Triglycerides at Weeks 52 and 78</title>
        <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Triglycerides value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
        <time_frame>Baseline; Week 52 and Week 78</time_frame>
        <population>Safety Population. Only participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo; Bempedoic Acid</title>
            <description>In the parent study (Study 1002-040), participants received placebo tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 milligrams (mg) once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O2">
            <title>Bempedoic Acid; Bempedoic Acid</title>
            <description>In the parent study, participants received bempedoic acid 180 mg tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O3">
            <title>OLE Bempedoic Acid</title>
            <description>In the parent study, participants received either bempedoic acid 180 mg tablet or matching placebo, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From OLE Baseline in Triglycerides at Weeks 52 and 78</title>
          <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Triglycerides value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
          <population>Safety Population. Only participants with available data were analyzed.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="970"/>
                <count group_id="O3" value="1462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="464"/>
                    <count group_id="O2" value="909"/>
                    <count group_id="O3" value="1373"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="-22.4" upper_limit="23.6"/>
                    <measurement group_id="O2" value="0.9" lower_limit="-20.2" upper_limit="25.2"/>
                    <measurement group_id="O3" value="0.7" lower_limit="-20.7" upper_limit="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="433"/>
                    <count group_id="O2" value="865"/>
                    <count group_id="O3" value="1298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-23.8" upper_limit="24.1"/>
                    <measurement group_id="O2" value="2.2" lower_limit="-19.2" upper_limit="27.2"/>
                    <measurement group_id="O3" value="0.9" lower_limit="-20.9" upper_limit="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From OLE Baseline in HDL-C at Weeks 52 and 78</title>
        <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: HDL-C value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
        <time_frame>Baseline; Week 52 and Week 78</time_frame>
        <population>Safety Population. Only participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo; Bempedoic Acid</title>
            <description>In the parent study (Study 1002-040), participants received placebo tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 milligrams (mg) once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O2">
            <title>Bempedoic Acid; Bempedoic Acid</title>
            <description>In the parent study, participants received bempedoic acid 180 mg tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
          <group group_id="O3">
            <title>OLE Bempedoic Acid</title>
            <description>In the parent study, participants received either bempedoic acid 180 mg tablet or matching placebo, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From OLE Baseline in HDL-C at Weeks 52 and 78</title>
          <description>Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: HDL-C value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.</description>
          <population>Safety Population. Only participants with available data were analyzed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="970"/>
                <count group_id="O3" value="1462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="464"/>
                    <count group_id="O2" value="907"/>
                    <count group_id="O3" value="1371"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="18.36"/>
                    <measurement group_id="O2" value="-0.6" spread="14.88"/>
                    <measurement group_id="O3" value="-1.8" spread="16.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="433"/>
                    <count group_id="O2" value="863"/>
                    <count group_id="O3" value="1296"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="17.77"/>
                    <measurement group_id="O2" value="2.7" spread="23.60"/>
                    <measurement group_id="O3" value="0.7" spread="22.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Week 82</time_frame>
      <desc>Treatment-emergent adverse events, defined as adverse events that began or worsened in severity after the first dose of investigational medicinal product (IMP) until 30 days after the last dose in the Open-Label Extension (OLE) study, are reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo; Bempedoic Acid</title>
          <description>In the parent study (Study 1002-040), participants received placebo tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 milligrams (mg) once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of investigational medicinal product (IMP).</description>
        </group>
        <group group_id="E2">
          <title>Bempedoic Acid; Bempedoic Acid</title>
          <description>In the parent study, participants received bempedoic acid 180 mg tablet, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
        </group>
        <group group_id="E3">
          <title>OLE Bempedoic Acid</title>
          <description>In the parent study, participants received either bempedoic acid 180 mg tablet or matching placebo, once daily by mouth for 52 weeks. In addition, participants received stable background lipid-modifying therapy(ies), including a maximally tolerated statin, throughout the study. Participants received open-label bempedoic acid 180 mg once daily by mouth for up to 78 weeks after rolling over from the parent study, followed by a 4-week period off of IMP.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="202" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="299" subjects_at_risk="1462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Abdominal lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Splenic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Ventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Anginal equivalent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple endocrine neoplasia Type 1</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism primary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Large intestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Accidental death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Brain death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Vascular stent occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Vascular stent thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Lymph node tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Intestinal anastomosis complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Peripheral artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Periprocedural myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Stress echocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Ultrasound ovary abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Clear cell renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Extranodal marginal zone B-cell lymphoma (MALT type)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Hypergammaglobulinaemia benign monoclonal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage III</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Metastatic gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma of the skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Papillary renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Rectal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Toxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>External compression headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Unresponsive to stimuli</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Micturition disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Angiodysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Femoral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1462"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="201" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="309" subjects_at_risk="1462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="119" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="89" subjects_at_risk="1462"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="1462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="492"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="970"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="1462"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.&#xD;
If the Principal Investigator plans to publish information from the study, a copy of the manuscript should be provided to the Sponsor for review before submission for publication or presentation. The Sponsor may request that that publication be withheld.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Esperion Therapeutics, Inc.</organization>
      <phone>1-833-377-7633</phone>
      <email>medinfo@esperion.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

